Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases

Abstract

Background: Psoriasis, psoriatic arthritis, spondyloarthritis, rheumatoid arthritis, ulcerative colitis, and Crohn disease share similar underlying pathophysiological processes, providing the opportunity to treat the patients using similar biological therapies. Failure of biological treatments due to underexposure can be managed by therapeutic drug monitoring. Adjusting the treatment based on pharmacokinetic monitoring can be further improved by taking pharmacodynamic parameters such as clinical and molecular markers into account. Methods: Here, we critically evaluate the existing evidence, the hurdles to be taken, and the opportunities for a widespread implementation of pharmacodynamic monitoring. Results: Pharmacodynamic monitoring typically is the monitoring of biochemical markers. A pharmacodynamic marker preferably is specific for the pharmacological action of a drug, but most of the time nonspecific pharmacodynamic markers are used, such as C-reactive protein and the erythrocyte sedimentation rate. Clinical pharmacodynamic markers typically evaluate physical variables or symptoms. Although physician-reported outcomes have been studied for a longer time and often have been shown to correlate well with molecular pharmacodynamic markers and treatment outcomes, the introduction of mobile health or mHealth technologies caused a shift toward patient-reported outcomes, with the associated challenge to consistently reflect the inflammatory state, thereby preventing undertreatment or unnecessary overdosing of patients. Conclusions: The primary goal of pharmacodynamic monitoring is to optimize the response, but it can also have an impact on safety, costs, patient adherence, etc. Ideally, the constant remote monitoring of patient-reported disease activity is expected to become the standard, facilitated by mHealth technologies.

Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review

“…The uses of Constant Care to titrate treatment for flares or maintenance therapy are exciting and have been recognized as an early step in the pursuit of pharmacokinetic monitoring [70]. One single treatment of a biologic therapy like infliximab can cost thousands of dollars and require an entire day in an infusion center [71].…”

Medication‐related problems in chronic inflammatory conditions: A pharmacy claims and electronic health record analysis

“…The study focused on chronic inflammatory conditions because these are the most expensive specialty therapy drug class with respect to per‐member per‐year spending by commercial payers, and non‐adherence in this patient population has serious clinical and financial consequences both on an individual patient level and on a health‐systems level 6 . The following conditions were considered chronic inflammatory conditions for the purposes of this study: psoriasis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, and ankylosing spondylitis; these disease states are have been included in groupings of chronic inflammatory conditions in previous literature 2,11,12 …”

Evaluating the Chrono-pharmacology of Icosapent Ethyl to Assess its Therapeutic Efficacy in Reducing Hypertriglyceridemia Associated Cardiovascular Events

“…1,15,16 The pharmacological approach in the management of chronic diseases by default involves patients being on the medication indefinitely. [16][17][18][19] Although changes to the medication is considered in the events of any undesirable effects. [19][20][21] Chronic consumption of the medicines does lead to its progressive accumulation in several tissue niche and the pharmacokinetics and pharmacodynamics of such tissue specific accumulation of medicine is rarely investigated clinically probably due to lack of suitable protocols to investigate such impact.…”